SUCCESSFUL RE-TREATMENT WITH AZACITIDINE IN A PATIENT WITH MYELODYSPLASTIC SYNDROME (MDS) EVOLUTED INTO ACUTE MYELOID LEUKEMIA (AML) AFTER THE SUSPENSION OF THIS AGENT

被引：0
|
作者：
Niscola, P. [1 ]
Tendas, A. [1 ]
Cupelli, L. [1 ]
Scaramucci, L. [1 ]
Giovannini, M. [1 ]
Fratoni, S. [2 ]
de Fabritiis, P. [2 ]
机构：
[1] S Eugenio Hosp, Hematol, Rome, Italy
[2] S Eugenio Hosp, Dept Pathol, Rome, Italy
来源：
LEUKEMIA RESEARCH | 2015年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
274
引用
收藏
页码：S137 / S138
页数：3
相关论文
共 50 条
  • [21] A Phase II Study of Azacitidine and Sirolimus for the Treatment of Acute Myeloid Leukemia (AML) Refractory to or Not Eligible for Intensive Chemotherapy or High Risk Myelodysplastic Syndrome (MDS)
    Palmisiano, Neil
    Jeschke, Grace
    Wilde, Lindsay
    Leiby, Benjamin E.
    Alpdogan, Onder
    Carabasi, Matthew
    Filicko-O'Hara, Joanne
    Gaballa, Sameh
    Grosso, Dolores
    Klumpp, Thomas R.
    Outschoorn, Ubaldo Martinez
    Wagner, John L.
    Carroll, Martin
    Porcu, Pierluigi
    Flomenberg, Neal
    Perl, Alexander E.
    Kasner, Margaret
    BLOOD, 2017, 130
  • [22] CONNECT MDS AND AML: THE MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML) DISEASE REGISTRY
    Steensma, D.
    Abedi, M.
    Bejar, R.
    Cogle, C.
    Foucar, K.
    Garcia-Manero, G.
    George, T.
    Grinblatt, D.
    Komrokji, R.
    Maciejewski, J.
    Pollyea, D.
    Roboz, G.
    Savona, M.
    Scott, B.
    Sekeres, M.
    Thompson, M.
    Sugrue, M.
    Swern, A.
    Nifenecker, M.
    Erba, H.
    LEUKEMIA RESEARCH, 2015, 39 : S124 - S124
  • [23] Therapy-related myelodysplastic syndrome (t-MDS) following treatment of acute myeloid leukemia (AML)
    Arana-Yi, C.
    Block, A. W.
    Sait, S. N.
    Ford, L. A.
    Barcos, M.
    Baer, M. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] The pharmacokinetics of azacitidine following subcutaneous treatment in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML)
    Laille, E.
    Ward, R.
    Nasser, A.
    Stoltz, M.
    Cogle, C.
    Gore, S.
    Skikne, B. S.
    Garcia-Manero, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] Differentiation syndrome in acute myeloid leukemia after treatment with azacitidine
    Laufer, Christin B.
    Roberts, Owen
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (05) : 484 - 485
  • [26] Acquired chromosomal aberrations in children with Down syndrome and myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
    Teigler-Schlegel, A
    Baumann, I
    Creutzig, U
    Niemeyer, C
    Harbott, J
    LEUKEMIA, 2000, 14 (05) : 966 - 966
  • [27] Lenalidomide and Risk of Acute Myeloid Leukemia (AML) Transformation Among Myelodysplastic Syndrome (MDS) Patients
    Rollison, Dana E.
    Shain, Kenneth H.
    Lee, Ji-Hyun
    Hampras, Shalaka S.
    Fulp, William
    Fisher, Kate
    Al Ali, Najla H.
    Padron, Eric
    Lancet, Jeffrey
    Xu, Qiang
    Knight, Robert D.
    List, Alan F.
    Dalton, William
    Komrokji, Rami
    BLOOD, 2014, 124 (21)
  • [28] Analysis of mutations associated with response to glasdegib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
    Ching, Keith A.
    Huang, Donghui
    Wang, Kai
    Ozeck, Mark
    Lira, Paul
    Gao, Jingjin
    Bienkowska, Jadwiga
    Rejto, Paul
    Hardwick, James
    O'Brien, Thomas
    Chan, Geoffrey
    CANCER RESEARCH, 2018, 78 (13)
  • [29] Relationship of progression to acute myeloid leukemia (AML) from myelodysplastic syndrome (MDS) and cytogenetic status
    Hellstrom-Lindberg, E.
    Fenaux, P.
    Mufti, G. J.
    List, A. F.
    Santini, V.
    Gore, S.
    Seymour, J. F.
    Backstrom, J.
    McKenzie, D.
    Beach, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [30] Clinical relevance of circulating myeloperoxidase (MPO) in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
    Jilani, I
    Vincenti, T
    Faraji, H
    Giles, FJ
    Estey, E
    Kantarjian, HM
    Albitar, M
    BLOOD, 2004, 104 (11) : 305A - 305A
12345